Tada, always good to hear something positive, so thanks for that. The stock is in the doghouse because we're not hearing anything on the Covid trial and, by extension, BoM2 now seems a long way off, especially in this Covid world. As a result some folks are bailing and, being a thinly traded stock, it doesn't take much to drive down the price.

I would have to think that the company is doing what it can to get the Covid trial moving but they don't have total control over that.  I would imagine it's as frustrating for them as it is for everyone on this board.

The potential benefits of Apabetalone seem reasonably well established in the scientific community, and the addition of Eversana does indicate that a commercial benefit is a real possibility.  But, it all comes down to clinical trial success and it's impossible to establish that without that actually happening.  So, here we are.